Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose- Fractionation in the RADICALS-RT Trial

被引:4
|
作者
Petersen, Peter Meidahl [1 ]
Cook, Adrian D. [2 ]
Sydes, Matthew R. [2 ]
Clarke, Noel [3 ]
Cross, William [4 ]
Kynaston, Howard [5 ]
Logue, John [6 ]
Neville, Peter [2 ]
Parmar, Mahesh K. B. [2 ]
Parulekar, Wendy [8 ]
Persad, Rajendra [9 ]
Saad, Fred [10 ]
Stirling, Alan [11 ]
Parker, Christopher C. [12 ]
Catton, Charles [13 ]
机构
[1] Copenhagen Univ Hosp, Dept Oncol, Rigshosp, Copenhagen, Denmark
[2] UCL, Med Res Council Clin Trials Unit UCL, Inst Clin Trials & Methodol, London, England
[3] Univ Manchester, Christie & Salford Royal Hosp, Dept Urol, Manchester, Lancs, England
[4] St James Univ Hosp, Dept Urol, Leeds, W Yorkshire, England
[5] Univ Hosp Wales, Cardiff, Wales
[6] Christie NHS Fdn Trust, Manchester, Lancs, England
[7] UCL, Prostate Ctr, London, England
[8] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[9] North Bristol Hosp, Bristol Urol Inst, Bristol, Avon, England
[10] Ctr Hosp Univ Montreal, Urol Oncol, Montreal, PQ, Canada
[11] Castle Hill Hosp, Castle Rd, Cottingham, England
[12] Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England
[13] Univ Hlth Network, Princess Margaret Hosp, Radiat Oncol, Toronto, ON, Canada
关键词
ADJUVANT RADIOTHERAPY; NON-INFERIORITY; CANCER; PHASE-3;
D O I
10.1016/j.ijrobp.2023.04.032
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Emerging data indicate comparable disease control and toxicity of normal postoperative fractionation and moderate hypofractionation radiation therapy (RT) in prostate cancer. In RADICALS-RT, patients were planned for treatment with either 66 Gy in 33 fractions (f) over 6.5 weeks or 52.5 Gy in 20f over 4 weeks. This non-randomized, exploratory analysis explored the toxicity of these 2 schedules in patients who had adjuvant RT. Methods and Materials: Information on RT dose was collected in all patients. The Radiation Therapy Oncology Group toxic-ity score was recorded every 4 months for 2 years, every 6 months until 5 years, then annually until 15 years. Patient-reported data were collected at baseline and at 1, 5, and 10 years using standard measures, including the Vaizey fecal incontinence score (bowel) and the International Continence Society Male Short-Form questionnaire (urinary incontinence). The highest event grade was recorded within the first 2 years and beyond 2 years and compared between treatment groups using the chi(2) test. Results: Of 634 patients, 217 (34%) were planned for 52.5 Gy/20f and 417 (66%) for 66 Gy/33f. In the first 2 years, grade 1 to 2 cystitis was reported more frequently among the 66 Gy/33f group (52.5 Gy/20f: 20% vs 66 Gy/33f: 30%; P = .04). After 2 years, grade 1 to 2 cystitis was reported in 16% in the 66-Gy group and 9% in the 52.5-Gy group (P = .08). Other toxic effects were similar in the 2 groups, and very few patients had any grade 3 to 4 toxic effects. Patients reported slightly higher urinary and fecal incontinence scores at 1 year than at baseline, but no clinically meaningful differences were reported between the 52.5 Gy/20f and 66 Gy/33f groups. Patient-reported health was similar at baseline and at 1 year and similar between the 52.5 Gy/20f and 66 Gy/33f groups. Conclusions: Severe toxic effects were rare after prostate bed radiation therapy with either 52.5 Gy/20f or 66 Gy/33f. Only modest differences were recorded in toxic effects or in patient-reported outcomes between these 2 schedules. Crown Copyright (c) 2023 Published by Elsevier Inc. All rights reserved.
引用
下载
收藏
页码:624 / 629
页数:6
相关论文
共 50 条
  • [11] Salvage radiation therapy after radical prostatectomy: Contribution of a dose escalation to macroscopic local relapses
    Selmaji, Imad Eddine
    Udrescu, Corina
    Brahmi, Tristan
    Samlali, Hamza
    Lapierre, Ariane
    Enachescu, Ciprian
    Ruffion, Alain
    Chapet, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [12] Radiation therapy (RT) after prostatectomy:: The case for salvage therapy as opposed to adjuvant therapy
    Schild, SE
    INTERNATIONAL JOURNAL OF CANCER, 2001, 96 (02) : 94 - 98
  • [13] Adjuvant Radiation Therapy versus early Salvage Radiation Therapy after radical Prostatectomy
    Lenzen, J.
    Feldmann, H. J.
    ONKOLOGE, 2021, 27 (06): : 610 - 612
  • [14] Toxicity following high-dose salvage radiotherapy after radical prostatectomy
    Jung, Charlie
    Cookson, Michael S.
    Chang, Sam S.
    Smith, Joseph A., Jr.
    Dietrich, Mary S.
    Teng, Ming
    BJU INTERNATIONAL, 2007, 99 (03) : 529 - 533
  • [15] Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate
    Catton, C
    Gospodarowicz, M
    Warde, P
    Panzarella, T
    Catton, P
    McLean, M
    Milosevic, M
    RADIOTHERAPY AND ONCOLOGY, 2001, 59 (01) : 51 - 60
  • [16] Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy
    Hawken, Scott R.
    Spratt, Daniel E.
    Linsell, Susan M.
    Cher, Michael L.
    Ghani, Khurshid R.
    Miller, David C.
    Montie, James E.
    Morgan, Todd M.
    Qi, Ji
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (05): : 1030 - 1034
  • [17] Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy
    S Egawa
    M Ohori
    M Iwamura
    S Kuwao
    S Baba
    Prostate Cancer and Prostatic Diseases, 1999, 2 : S12 - S12
  • [18] Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy
    Leonardo, Costantino
    Simone, Giuseppe
    Papalia, Rocco
    Franco, Giorgio
    Guaglianone, Salvatore
    Gallucci, Michele
    INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (06) : 584 - 586
  • [19] Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate
    Wiegel, T
    Hinkelbein, W
    RADIOTHERAPY AND ONCOLOGY, 2002, 62 (01) : 115 - 115
  • [20] UTILIZATION OF SALVAGE RADIATION THERAPY FOR BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
    Hawken, Scott
    Spratt, Daniel E.
    Qi, Ji
    Linsell, Susan M.
    Cher, Michael L.
    Ghani, Kurshid R.
    Miller, David C.
    Montie, James E.
    Morgan, Todd M.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E272 - E272